AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25862350 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 825 mg/m² twice daily on days 1-21 every 4 weeks
Number of subjects: 142
Study 25862350 — intervention group
Group type: COMPARATOR
Intervention: S-1 40-60 mg twice daily on days 1-28 every 6 weeks
Number of subjects: 142
Study 25862350 — intervention group
Group type: COMPARATOR
Intervention: S-1
Number of subjects: 142
Study 25862350 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 142
Study 23799280 — intervention group
Group type: EXPERIMENTAL
Intervention: VIPON tampon
Number of subjects: 0
Study 23799280 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (200-400 mg)
Number of subjects: 0
Study 17594077 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific segmental muscle training program of the lumbar spine (12 weeks duration).
Number of subjects: 42
Study 17594077 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention).
Number of subjects: 42
Study 17594077 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific segmental muscle training program of the lumbar spine.
Number of subjects: 42
Study 15025612 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with 5 mg of bupivacaine diluted with sterile water to 2.5-ml volume (SPIN-group)
Number of subjects: 70
Study 15025612 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia with spontaneous breathing via a laryngeal mask (GA-group)
Number of subjects: 70
Study 10716136 — intervention group
Group type: EXPERIMENTAL
Intervention: E/O2 slope <27.6 and left ventricular ejection fraction >28% (n=18)
Number of subjects: 60
Study 10716136 — intervention group
Group type: EXPERIMENTAL
Intervention: E/O2 slope >27.6 and left ventricular ejection fraction >28% (n=12)
Number of subjects: 60
Study 9307822 — intervention group
Group type: EXPERIMENTAL
Intervention: Sway magnetometry measurement before and after informing the subject that the test was starting (15 seconds before and 15 seconds after).
Number of subjects: 47
Study 9307822 — intervention group
Group type: COMPARATOR
Intervention: Sway magnetometry measurement for normal subjects and organic dizziness subjects.
Number of subjects: 47
Study 8212757 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg nizatidine nocte (n = 86)
Number of subjects: 269
Study 8212757 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 150 mg/d nizatidine (n = 93)
Number of subjects: 269
Study 8212757 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 300 mg/d nizatidine (n = 90)
Number of subjects: 269
Study 8212757 — intervention group
Group type: EXPERIMENTAL
Intervention: nizatidine 150 mg nocte (n = 116) in prophylactic trial
Number of subjects: 269
Study 8212757 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 150 mg nizatidine daily (n = 121) in prophylactic trial
Number of subjects: 269
Study 3535187 — intervention group
Group type: COMPARATOR
Intervention: Daily short course chemotherapy (6-month) with regimens containing streptomycin, isoniazid, rifampicin, and pyrazinamide in the initial phase; isoniazid plus rifampicin or isoniazid plus rifampicin and/or pyrazinamide in the continuation phase.
Number of subjects: 0
Study 3535187 — intervention group
Group type: COMPARATOR
Intervention: Daily short course chemotherapy (6-month)
Number of subjects: 0
Study 31318258 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived momentum in sequential events
Number of subjects: 0
Study 31318258 — intervention group
Group type: EXPERIMENTAL
Intervention: Events that break streaks (e.g., incorrect guesses)
Number of subjects: 0
Study 31004325 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-free insulin injector
Number of subjects: 420
Study 31004325 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin pen
Number of subjects: 420
Study 28734823 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg daily for up to 28 days
Number of subjects: 142
Study 28734823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 28734823 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 142
Study 26512232 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial participation
Number of subjects: 25
Study 26512232 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust in family practitioner (FP)
Number of subjects: 25
Study 26512232 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety concerning symptom relief
Number of subjects: 25
Study 26512232 — intervention group
Group type: COMPARATOR
Intervention: Individual treatment preferences
Number of subjects: 25
Study 23388664 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense individualized dietary advice (dietetic follow-up fortnightly for 6 months)
Number of subjects: 27
Study 23388664 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 27
Study 22069986 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous periosteum wrapping tendon allograft
Number of subjects: 68
Study 22069986 — intervention group
Group type: COMPARATOR
Intervention: Simple tendon allograft
Number of subjects: 68
Study 19631949 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (PGB) 150-600 mg/day
Number of subjects: 20
Study 19631949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16720762 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty (THA)
Number of subjects: 120
Study 16720762 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface Replacement Arthroplasty (SRA)
Number of subjects: 120
Study 16720762 — intervention group
Group type: COMPARATOR
Intervention: Control (contralateral hip)
Number of subjects: 120
Study 14668658 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency thermocoagulation of the ramus communicans nerve (lesion group)
Number of subjects: 49
Study 14668658 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine injection (control group)
Number of subjects: 49
Study 11480533 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum Depression Screening Scale (PDSS)
Number of subjects: 150
Study 11480533 — intervention group
Group type: COMPARATOR
Intervention: Edinburgh Postnatal Depression Scale (EPDS)
Number of subjects: 150
Study 11480533 — intervention group
Group type: COMPARATOR
Intervention: Beck Depression Inventory‐II (BDI‐II)
Number of subjects: 150
Study 9267946 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine infusion at 6.0 microg/kg/min
Number of subjects: 8
Study 9267946 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine infusion at 3.0 microg/kg/min
Number of subjects: 8
Study 9267946 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine infusion at all rates (0.75, 1.5, 3.0, and 6.0 microg/kg/min)
Number of subjects: 8
Study 9267946 — intervention group
Group type: COMPARATOR
Intervention: Control period (no dopexamine)
Number of subjects: 8
Study 8305657 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cardioplegia (BCP)
Number of subjects: 100
Study 8305657 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid cardioplegia (CCP)
Number of subjects: 100
Study 3302866 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime IV (100 mg.kg‐1 D‐1) plus netilmicin (4 mg.kg‐1 D‐1)
Number of subjects: 22
Study 3302866 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid IV (100/10 mg.kg‐1 D‐1) plus netilmicin (4 mg.kg‐1 D‐1)
Number of subjects: 22
Study 30352626 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg
Number of subjects: 30
Study 30352626 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg
Number of subjects: 30
Study 30352626 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant ipilimumab‐HDI
Number of subjects: 30
Study 27269741 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg
Number of subjects: 216
Study 27269741 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 1 mg/kg plus ipilimumab 1 mg/kg
Number of subjects: 216
Study 27269741 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg
Number of subjects: 216
Study 27269741 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg plus ipilimumab 1 mg/kg
Number of subjects: 216
Study 25129520 — intervention group
Group type: EXPERIMENTAL
Intervention: AUC-based educational intervention
Number of subjects: 100
Study 25129520 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 21996521 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimorazole
Number of subjects: 323
Study 21996521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study 20298924 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 4543
Study 20298924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4543
Study 18680975 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia schemes
Number of subjects: 0
Study 18680975 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy schemes
Number of subjects: 0
Study 16422888 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor
Number of subjects: 59
Study 16422888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 12829908 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab 1 mg/kg immediately after liver transplantation
Number of subjects: 81
Study 12829908 — intervention group
Group type: COMPARATOR
Intervention: Control group (no induction therapy)
Number of subjects: 81
Study 12829908 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab group
Number of subjects: 81
Study 12829908 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study 10791000 — intervention group
Group type: COMPARATOR
Intervention: Conventional full-dose docetaxel (FD) 60 mg/m2 every 3 or 4 weeks (group I)
Number of subjects: 60
Study 10791000 — intervention group
Group type: COMPARATOR
Intervention: Low-dose weekly docetaxel (LD) 20-30 mg/m2 every week (group II)
Number of subjects: 60
Study 10791000 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose weekly docetaxel (LD) 20-30 mg/m2 weekly with oral 5'-DFUR 600-1,200 mg per day (LD + D, group III)
Number of subjects: 60
Study 8646099 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundholding practices
Number of subjects: 108300
Study 8646099 — intervention group
Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 108300
Study 1513941 — intervention group
Group type: COMPARATOR
Intervention: PCADF (intravenous conventional PCA at fixed demand doses)
Number of subjects: 30
Study 1513941 — intervention group
Group type: EXPERIMENTAL
Intervention: PCADV (demand doses varied according to pain intensity)
Number of subjects: 30
Study 1513941 — intervention group
Group type: COMPARATOR
Intervention: PCAC + DV (continuous infusion with additional demand doses in variable bolus)
Number of subjects: 30
Study 6390928 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone (third-generation cephalosporin)
Number of subjects: 0
Study 6390928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30664524 — intervention group
Group type: EXPERIMENTAL
Intervention: Face mask
Number of subjects: 50
Study 30664524 — intervention group
Group type: COMPARATOR
Intervention: HFNO
Number of subjects: 50
Study 30407312 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1200 mg/d
Number of subjects: 0
Study 30407312 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study 26610643 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 2502
Study 26610643 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 2502
Study 24253758 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐glucan (BG)
Number of subjects: 15
Study 24253758 — intervention group
Group type: EXPERIMENTAL
Intervention: rye bread with kernels (RK)
Number of subjects: 15
Study 24253758 — intervention group
Group type: EXPERIMENTAL
Intervention: concentrated arabinoxylan (AX)
Number of subjects: 15
Study 24253758 — intervention group
Group type: COMPARATOR
Intervention: refined wheat bread (WB)
Number of subjects: 15
Study 22124880 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 28
Study 22124880 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 28
Study 20664343 — intervention group
Group type: EXPERIMENTAL
Intervention: Superpulsed low-level laser therapy (SLLLT)
Number of subjects: 99
Study 20664343 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory drugs (ibuprofen 800 mg twice a day for 10 days)
Number of subjects: 99
Study 20664343 — intervention group
Group type: COMPARATOR
Intervention: Sham laser (placebo)
Number of subjects: 99
Study 17468357 — intervention group
Group type: EXPERIMENTAL
Intervention: CGMS/KADIS
Number of subjects: 49
Study 17468357 — intervention group
Group type: COMPARATOR
Intervention: CGMS
Number of subjects: 49
Study 15911687 — intervention group
Group type: EXPERIMENTAL
Intervention: Job social skills training
Number of subjects: 92
Study 15911687 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial management skills training
Number of subjects: 92
Study 12696648 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstitution of drinking water in the miners' workplace
Number of subjects: 150
Study 12696648 — intervention group
Group type: COMPARATOR
Intervention: Before water reconstitution
Number of subjects: 150
Study 12696648 — intervention group
Group type: EXPERIMENTAL
Intervention: After water reconstitution
Number of subjects: 150
Study 9602222 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic solution under occlusion
Number of subjects: 15
Study 9602222 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusion only
Number of subjects: 15
Study 9602222 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 15
Study 7747581 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine, bupivacaine, adrenaline and hyaluronidase
Number of subjects: 54
Study 7747581 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine and bupivacaine
Number of subjects: 54
Study 2598475 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine administration
Number of subjects: 21
Study 2598475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 4685317 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization on day 10
Number of subjects: 203
Study 4685317 — intervention group
Group type: COMPARATOR
Intervention: Mobilization on day 20
Number of subjects: 203
Study 31977567 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide autogel/depot 120 mg
Number of subjects: 201
Study 31977567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 31894027 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine controlled-release tablets combined with valsartan
Number of subjects: 180
Study 31894027 — intervention group
Group type: COMPARATOR
Intervention: Valsartan dispersible tablets
Number of subjects: 180
Study 28813218 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 2203
Study 28813218 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 2203
Study 25249172 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone iodine solution (0.5 mg/mL)
Number of subjects: 30
Study 25249172 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 30
Study 24050860 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (TAT)
Number of subjects: 3755
Study 24050860 — intervention group
Group type: COMPARATOR
Intervention: Double-dose clopidogrel dual antiplatelet therapy (DDAT)
Number of subjects: 3755
Study 24050860 — intervention group
Group type: EXPERIMENTAL
Intervention: TAT
Number of subjects: 3755
Study 24050860 — intervention group
Group type: COMPARATOR
Intervention: DDAT
Number of subjects: 3755
Study 24050860 — intervention group
Group type: COMPARATOR
Intervention: TAT and DDAT
Number of subjects: 3755
Study 21334061 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 641
Study 21334061 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Exercise Therapy (GET)
Number of subjects: 641
Study 21334061 — intervention group
Group type: COMPARATOR
Intervention: Adaptive Pacing Therapy (APT)
Number of subjects: 641
Study 21334061 — intervention group
Group type: COMPARATOR
Intervention: Specialist Medical Care (SMC)
Number of subjects: 641
Study 19186714 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic moxibustion added to routine chemotherapeutic program
Number of subjects: 53
Study 19186714 — intervention group
Group type: COMPARATOR
Intervention: Routine chemotherapeutic program of western medicine
Number of subjects: 53
Study 16850682 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 hour-supine recumbence
Number of subjects: 65
Study 16850682 — intervention group
Group type: COMPARATOR
Intervention: Early ambulation (<= 1 hour)
Number of subjects: 65
Study 14691381 — intervention group
Group type: EXPERIMENTAL
Intervention: Socially anxious individuals
Number of subjects: 46
Study 14691381 — intervention group
Group type: COMPARATOR
Intervention: Nonsocially anxious controls
Number of subjects: 46
Study 10882444 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable interference screw for femoral fixation and titanium interference screw for tibial fixation (Group A)
Number of subjects: 40
Study 10882444 — intervention group
Group type: COMPARATOR
Intervention: Titanium interference screws for both femoral and tibial fixation (Group B)
Number of subjects: 40
Study 8769360 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-fat group
Number of subjects: 68
Study 8769360 — intervention group
Group type: COMPARATOR
Intervention: Reduced-fat group
Number of subjects: 68
Study 1576630 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin (I-C)
Number of subjects: 49
Study 1576630 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin+aminoglycoside (C+A)
Number of subjects: 49
Study 3930683 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 1-[13C]acetate
Number of subjects: 5
Study 3930683 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal administration of 1-[13C]acetate
Number of subjects: 5
Study 3806876 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum cholesterol level
Number of subjects: 361662
Study 3806876 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual measurements of serum cholesterol level in the randomized trial
Number of subjects: 361662
Study 3806876 — intervention group
Group type: COMPARATOR
Intervention: High serum cholesterol level
Number of subjects: 361662
Study 31514191 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy plus intra-articular methylprednisolone injection
Number of subjects: 52
Study 31514191 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 52
Study 29143570 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity, low-load (40% of predicted one repetition maximum)
Number of subjects: 10
Study 29143570 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-velocity, high-load (80% of predicted one repetition maximum)
Number of subjects: 10
Study 28333482 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim test group (completed a recall test after each list)
Number of subjects: 0
Study 28333482 — intervention group
Group type: COMPARATOR
Intervention: No interim test group (only tested on the final list)
Number of subjects: 0
Study 28333482 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim test group
Number of subjects: 0
Study 26248726 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus a glaucoma personal record detailing the current state of their condition
Number of subjects: 122
Study 26248726 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical care (control arm)
Number of subjects: 122
Study 26248726 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus a glaucoma personal record
Number of subjects: 122
Study 23970941 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice (8 ounces daily for 4 weeks)
Number of subjects: 32
Study 23970941 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (flavor-matched, 8 ounces daily for 4 weeks)
Number of subjects: 32
Study 21420053 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate plus sodium chloride (bicarbonate group, n = 78)
Number of subjects: 155
Study 21420053 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride alone (chloride group, n = 77)
Number of subjects: 155
Study 21420053 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate plus sodium chloride (bicarbonate group)
Number of subjects: 155
Study 18656300 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest compression-only CPR
Number of subjects: 223
Study 18656300 — intervention group
Group type: COMPARATOR
Intervention: Conventional CPR
Number of subjects: 223
Study 16141376 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-receptor antagonist (300 mg oral ranitidine)
Number of subjects: 10
Study 16141376 — intervention group
Group type: COMPARATOR
Intervention: Control (no ranitidine)
Number of subjects: 10
Study 14603191 — intervention group
Group type: EXPERIMENTAL
Intervention: Microthrombectomy in group 1 (veins 1 mm or less)
Number of subjects: 101
Study 14603191 — intervention group
Group type: COMPARATOR
Intervention: Control side in group 1 (veins 1 mm or less)
Number of subjects: 101
Study 14603191 — intervention group
Group type: EXPERIMENTAL
Intervention: Microthrombectomy in group 2 (veins 3 mm or less)
Number of subjects: 101
Study 14603191 — intervention group
Group type: COMPARATOR
Intervention: Control side in group 2 (veins 3 mm or less)
Number of subjects: 101
Study 10848875 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid‐heparin emulsion (Li‐He, Intralipid 10% 250 ml + heparin 2500 U iv from ‐60 to + 90 minutes)
Number of subjects: 15
Study 10848875 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (ACI, 250 mg p.o. at ‐60 minutes)
Number of subjects: 15
Study 8838168 — intervention group
Group type: EXPERIMENTAL
Intervention: Various manipulations of boundary of visual field (ellipse and circle), bodily orientation (upright and lying), and orientation of visual objects (normal, 90 degrees-tilted, and inverse) in eight experiments.
Number of subjects: 8